Varegacestat’s pivotal study reads out imminently.
ApexOnco Front Page
Recent articles
The pivotal Harmoni-GI3 study has started enrolling patients.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
ASH and SABCS approach.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
The project has priority review, but deaths could raise eyebrows.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
An in vivo Car-T produced a 100% response rate – in three patients.
